antitumor effects of Xiao-Chai-Hu-Tang (Shosaiko-To: SHX) with or without 5-fluorouracil (5-FU) or cyclophosphamide (CY) were examined in an experimental system of lung metastasis induced by Lewis lung carcinoma in C57BL/ 6crSIc mice. Lewis lung carcinoma cells were implanted into the footpads of the mice. Ten days later, the implanted tumors were surgically removed.
Abstract-The
antitumor effects of Xiao-Chai-Hu-Tang (Shosaiko-To: SHX) with or without 5-fluorouracil (5-FU) or cyclophosphamide (CY) were examined in an experimental system of lung metastasis induced by Lewis lung carcinoma in C57BL/ 6crSIc mice. Lewis lung carcinoma cells were implanted into the footpads of the mice. Ten days later, the implanted tumors were surgically removed.
The effects of SHX were evaluated by the number of lung surface nodules present 14 days after removal of the implanted tumor. The administration of SHX, p.o. (300 mg/kgx2/ day x10) caused the antimetastatic effect. Therapy with SHX plus 5-FU or CY sig nificantly inhibited the development of lung metastases.
The number of peritoneal macrophages and the degree of the binding of C3 cleavage products (C3b) to macrophages were enhanced in the mice treated with SHX. Lung metastases were inhibited by the i.v. administration of peritoneal macrophages activated with SHX, p.o. These findings raise the possibility that SHX may have clinical value in the prevention of cancer metastasis. Assay of antitumor activity: For the early Lewis lung carcinoma system, tumor growth inhibition was determined by comparing the mean survival time of the treated animals (T) with that of the control (saline-treated) tumor-bearing animals (C). The percentage increase in life span (T/C%) was measured by the method we reported previously (15). As for the lung metastasis system: 10 days after implantation, when the tumor (105 cells/mouse) implanted in the footpad had become about 4 to 5 mm in diameter, each mouse was anesthetized by i.p. injection of Phagocytosis and C3 cleavage product binding assay: Some of the mice were administered p.o. 300 mg/kg of SHX twice a day, for 10 days. The control mice received only saline. The peritoneal macrophages were obtained as described above (17). The number of adherent cells was determined by wells. After extensive washing, a 0.25 mm2 area that included several different well areas was routinely counted (18). The adherent cells (4X105) on the coverslips were dried and then fixed in 95% ethanol for 20 min. Next they were dried again, covered with anti-mouse C3 F(ab')2 (prepared by treating anti-mouse C3 rabbit IgG with pepsin) and reincubated for 1 hr at 37°C. After the incubation, the cells were rinsed thoroughly with PBS (pH 7.2) and stained with goat FITC-anti-rabbit IgG at room temperature for 1 hr. Then they were washed thoroughly again with PBS (pH 7.2), mounted in a buffered glycerol (pH 9.5), and examined under a microscope (x400). About 200 adherent cells were counted on each slide. Based on this, the percentage of C3-positive fluorescent cells was calculated (18).
Statistical differences between the control and experimental treated groups were evaluated by using Student's t-test. Table 2 .
Effects of different routes of SHX administration on early Lewis lung carcinoma system Table 2 , the oral administration of SHX resulted in a 120% T/C% when a dose of 300 mg/kg x 2/day was given for 10 consecutive days. However, with SHX doses of 150 mg/kg x 2/day and 600 mg/kg x 2/day, the antitumor effect was decreased. These results indicate that there is an optimal dose of SHX for inhibiting the growth of Lewis lung carcinoma. SHX had no inhibitory effect when injected i.p. into mice.
Antitumor effects of 5-FU and CY against early Lewis lung carcinoma: The results of using 5-FU and CY to treat early Lewis lung carcinoma are shown in Table 3 . The deviation of survival time among 12 tumor bearing mice was 24.9±1.7 (S.E.) days. Antitumor activity was determined from the ratio of median life-span between the treated and control groups. CY was markedly active, causing an increase in life-span of 87% (over controls) at 30 mg/kg/day.
With CY at 20 mg/kg/day, median life-span increased by 40%. 5-FU at 30 mg/kg/day caused an increase of 37%. CY was more effective than 5-FU at similar doses. However, the median survival time of mice treated with 50 mg/kg/ day of CY was shorter than that of controls.
All animals were autopsied at death and observed for gross evidence of Lewis lung tumors. Nearly all of the mice in the control group showed gross lung tumor involvement. No metastatic nodules could be seen in 5 of 6 mice treated with 30 mg/kg/day of CY (the optimal dose), whereas it was observed in 4 of 6 mice treated with 50 mg/kg/day of 5-FU (higher than the optimal dose). CY was more effective than 5-FU, both in the suppression of tumor growth and in the prevention of lung metastasis.
Additive effects of SHX and 5-FU or CY on lung metastasis: The effects of combining SHX with 5-FU or CY to inhibit the metastasis of Lewis lung carcinoma were examined. The drugs were given p.o. after removal of the implanted primary tumor. As shown in Table 4 Effects of SHX on macrophage accumu lation and induction of C3-positive macro phages: The dose of SHX used in this experi ment is based on the antitumor effects observed in vivo. The maximum antitumor effect occurred after p.o. administration of 300 mg/kg x 2/day to Lewis lung carcinoma bearing mice. As shown in Table 6 , a marked accumulation of macrophages in the peri toneal cavity was observed 5-7 days after p.o. administration of the SHX.. In contrast, the number of peritoneal macrophages seen in the mice who received saline did not increase during a 10-day period. As shown in Fig. 1, C3 cleavage caused many macro phages to be brightly positive in immuno fluorescence after p.o. administration of the SHX. Table 6 shows that the C3-positive macrophages reached their maximum levels during Days 5-7. The macrophages were most brightly positive (about 65.0% of the cells) 7 days after SHX administration. However, in the control (saline) group, only 9.6% showed immunofluorescence on Day 7. The present study was undertaken to investigate the effects of SHX on Lewis lung carcinoma growth and on the formation of blood-borne metastasis. By itself, SHX not only inhibited the growth of Lewis lung carcinoma, but also reduced the number of metastatic nodules in the lung. SHX is a unique substance in that it shows greater antitumor effects by oral administration than by parenteral administration. CY and 5-FU were each effective in preventing lung micrometastasis in synge neic mice after the removal of Lewis lung carcinoma implanted in the footpad. We also found that SHX plus CY or SHX plus 5-FU had additive inhibitory effects on lung metastasis. The potency of SHX plus CY was greater than that of SHX plus 5-FU. These results are consistent with observations of the effects of CY and a glucan (schizo phyllan) on Lewis lung carcinoma-bearing mice (26).
We also demonstrated that i.v. injections of peritoneal macrophages activated with SHX inhibited the development of lung micrometastasis. Thus, the antimetastatic activity and the antitumor effect of SHX on lung carcinoma seems to be mediated by the activation of macrophages. Ito et al. (27) reported that adherent peritoneal exudate cells, harvested from mice after i.p. injections of squalene-treated Nocardia rubra cell wall skeleton (N-CWS), showed cytolytic activity on tumor target cells in vitro. They also found that this activity was markedly inhibited by treatment with antimacrophage serum and complement or carrageenan. Moreover, Liotta et al. (28) 
